A new US study in BMJ Open links legal cannabis sales to a faster rise in hospital admissions for heart failure, heart attack, and atrial fibrillation. The headlines sound clear-cut, but the data are not. The study measured entire regions, not the consumption of individual people.
📑 Inhaltsverzeichnis
How the Cannabis and Heart Hospitalizations Study Was Designed
A team led by Samuel Slavin from Boston University and Harvard T.H. Chan School of Public Health leveraged a unique feature of the US market. Legal recreational sales began in the western census region in January 2014, but didn’t start in the rest of the country until November 2018. The researchers analyzed the National Inpatient Sample from 2012 to 2018—covering 50,042,564 discharge records—using a difference-in-differences analysis to compare how admission rates changed in the West versus the rest of the country.
The Results: Three Diagnoses Rise, Three Don’t
After full adjustment, each year of legal sales was associated with relative increases in three diagnoses. Heart failure showed a 3.7 percent increase (95% CI 2.9 to 4.6), heart attack 3.1 percent (1.4 to 4.8), and atrial fibrillation 2.3 percent (1.0 to 3.5). For ischemic stroke, venous thromboembolism, and ventricular tachycardia, the association remained statistically insignificant.
The units matter here. These percentages describe differences in the trend of per-capita admission rates. They do not mean that a person consuming cannabis carries a 3.1 percent higher heart attack risk. Even the authors speak only of an association, not causation.
What Supports This Analysis
Methodologically, the work is sound. It includes controls that many similar analyses omit. Admissions with cannabis diagnoses rose as expected—13.8 percent per year. By contrast, kidney stone and opioid-related diagnoses showed no significant change, suggesting that a general trend in western hospital practice didn’t drive the results. The authors report no conflicts of interest; two received training fellowships from the NIH.
Where the Study’s Evidence Ends
The biggest weakness lies in the data foundation. Whether admitted patients actually consumed cannabis is unknown. According to the BMJ press release, neither the consumption method nor illegal use could be captured. Individual states couldn’t be analyzed separately either. That’s more than a footnote—the western region spans 13 states, and legal recreational dispensaries didn’t exist in all of them during the study period. Idaho, Utah, and Wyoming had none. The authors justify the comparison by noting that over 98 percent of the western population lived in or near a state with legal sales by 2018.
What else changed in the West remains unclear. The populations differed even at baseline: admitted patients there had a median age of 51 versus 55, and the non-white population share was 43 percent versus 33 percent. Adjustment accounts for measured variables only. The data also end in 2018, failing to reflect today’s market.
What This Means for Germany’s Cannabis Debate
The authors conclude that global legalization could lead to meaningful increases in cardiovascular care. This doesn’t simply apply to Germany. Here, home cultivation and growing associations exist, but not commercial retail on the US model. That market openings measurably change supply routes is shown by the Ohio study on legal sourcing. That a single regional comparison rarely has the final say is evident from our analysis of the Canadian study on crime around cannabis shops.
The finding shouldn’t be dismissed outright. It fits into a pattern we’ve already seen in the study on coronary heart disease with daily use. But the picture is not uniform, as the UCSF study on heart rhythm demonstrates. Our takeaway: the study doesn’t prove legalization causes harm, but it’s a strong argument for collecting cardiovascular data from day one in any regulation. The authors call for exactly that.
Frequently Asked Questions
Does the study prove cannabis causes heart attacks?
No. This is a regional-level observational study that cannot establish causation. Whether admitted patients actually used cannabis was never recorded.
What do the 3.1 percent figures for heart attack mean?
They describe how much more strongly the admission rate in the West rose per year of legal sales compared to comparison regions. No personal risk for consumers can be inferred from this.
Was a link to stroke also found?
Not in this analysis. The ischemic stroke value was slightly elevated but not statistically significant. The same applies to venous thromboembolism and ventricular tachycardia.
Can these results be applied to Germany?
Only very limitedly. The study examined commercial recreational sales in the US through 2018. Germany relies instead on home cultivation and growing associations, and the healthcare system and population differ significantly.
What should people with heart disease know?
THC can affect heart rate and temporarily raise blood pressure. Those with heart disease should discuss cannabis use—including medical cannabis—with their doctor. The study itself offers no individual recommendations.
Wie bewertest du Studien, die Cannabis mit Gesundheitsrisiken verbinden?
Sources: Slavin SD, Mahar AR, Secemsky EA, Yeh RW, Mittleman MA. Cannabis legalisation and cardiovascular hospitalisations in the United States: nationwide difference-in-differences analysis, 2012–2018. BMJ Open 2026;16(10):e111050, DOI 10.1136/bmjopen-2025-111050 (PubMed 42914544); BMJ Group Press Release (22.10.2026).
Branchen-Update
News, Analysen und Reportagen — mehrmals im Monat direkt in dein Postfach.
Folge uns
